The REDUCED (A R andomisED stU dy C omparing standard systemic anticoagulation thE rapy to low D ose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention
H. Ari,Eylem Kivaç,Selma Ari,N. Emlek,Seçkin Çetinkaya,Nuran Celiloğlu,O. Sarigul,C. Aydın,M. Akkaya,V. Koca,T. Bozat,Muhammet Gurdogan
DOI: https://doi.org/10.1080/AC.69.6.1000004
IF: 1.738
2014-12-01
Acta Cardiologica
Abstract:Aim This study tried to determine the effi cacy and safety of low-dose intracoronary unfractionated heparin (UFH) in elective percutaneous coronary intervention (PCI). Methods Two-hundred patients who underwent elective PCI of an uncomplicated lesion were included into the study. The patients were assigned to either a control group (70-100 IU/kg intravenous UFH) or a low-dose intracoronary UFH (1,000 IU intracoronary UFH) group. Results At 30 days, the primary end point (composite of death, myocardial infarction, or urgent target vessel revascularization) was similar in both groups [intracoronary UFH group, 1.0%; control group, 2.0%; odds ratio; 0.49 (95% CI: 0.04 - 5.54), P= 0.56]. Post-procedural myocardial injury (according to CK-MB, P= 0.91; according to Tn I, P= 0.81) and bleeding events (based on TIMI criteria, P= 0.33; based on STEEPLE criteria, P= 0.20) were similar in the control and intracoronary groups. The primary end point at 6 months was also similar between the two groups (P = 0.33). Moreover, the health care cost at 30 days of follow-up was lower in the intracoronary group than in the control group (1,016 ± 54 $/patient vs 1,110 ± 102 $/patient, P< 0.001). Conclusion This pilot study suggests that elective PCI could be safely performed with low-dose intracoronary UFH in the treatment of uncomplicated lesions and at a lower cost as compared to standard systemic anticoagulation. These results shou ld be confi rmed by further studies. Clinical trial registration number unique identifi er: NCT01031095